Tryptamine Therapeutics (AU:TYP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tryptamine Therapeutics, a clinical-stage biotech company, has altered its reporting status in Canada to a ‘designated foreign issuer’ while continuing to meet Australian regulatory requirements. The company has successfully completed Phase 2a clinical trials for binge eating disorder and fibromyalgia and is advancing trials on a proprietary IV-infused psilocin treatment designed to improve patient outcomes.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.